{"gene":"ITK","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":1995,"finding":"The kinase activity of Tsk/Itk is stimulated by G protein βγ subunits, demonstrated by co-transfection assays and in vitro reconstitution with purified bovine brain Gβγ subunits and immunoprecipitated Tsk, indicating Itk can act as an effector of heterotrimeric G proteins.","method":"Co-transfection assay and in vitro reconstitution with purified Gβγ subunits","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1 (in vitro reconstitution) + Weak (single lab, single study)","pmids":["7567982"],"is_preprint":false},{"year":1996,"finding":"The Itk SH3 domain binds specific proline-rich ligands including Sam68, Wiskott-Aldrich Syndrome protein (WASP), hnRNP-K, Grb-2, Cbl, and Fyn from TCR-stimulated Jurkat T cells, with the optimal SH3 binding motif defined by phage display library screening.","method":"Phage display library screening, SH3 domain pulldown from T cell lysates, deletion variant analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal pulldowns with multiple binding partners, phage display motif mapping, replicated with multiple proteins","pmids":["8810341"],"is_preprint":false},{"year":1997,"finding":"The Itk SH3 domain and proline-rich region interact intramolecularly, as determined by multidimensional NMR structure of an Itk fragment, representing the first example of intramolecular SH3-ligand interaction in a Tec family kinase. This interaction prevents the SH3 domain and proline-rich region from binding protein ligands (Sam68 and Grb-2), constituting an autoinhibitory mechanism.","method":"Multidimensional NMR structure determination, competitive binding assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with functional validation of autoinhibitory mechanism","pmids":["8985255"],"is_preprint":false},{"year":1997,"finding":"Lck directly transphosphorylates Itk on Tyr511 within the activation loop of the kinase domain, leading to increased Itk kinase activity. This was demonstrated by co-expression of recombinant Itk and Lck in a baculovirus system, and mutation of Tyr511 to Phe abolished Itk kinase activity.","method":"Baculovirus co-expression of recombinant proteins, in vitro kinase assay, site-directed mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro phosphorylation with mutagenesis confirming the critical activation-loop tyrosine","pmids":["9312162"],"is_preprint":false},{"year":1997,"finding":"Itk-deficient mice exhibit reduced primary cytotoxic T-lymphocyte (CTL) responses (by 2–6 fold) to LCMV, vaccinia virus, and VSV infection, while antiviral B cell antibody responses are unaffected. Exogenous IL-2 rescues in vitro CTL responses in Itk-deficient cells, indicating Itk is required for optimal T-cell but not B-cell antiviral immunity.","method":"Genetic knockout mouse model, ex vivo CTL assay, cytokine rescue experiment","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, cytokine rescue providing mechanistic insight","pmids":["9311799"],"is_preprint":false},{"year":1999,"finding":"The SH2 domains of Btk and Itk selectively bind tyrosine-phosphorylated SLP-65 (in B cells) and SLP-76 (in T cells), respectively, in activated lymphocytes. This restricted SH2 binding specificity is required for phospholipase C-γ phosphorylation and Ca²⁺ mobilization downstream of antigen receptors.","method":"SH2 domain binding assays with T/B cell lysates, co-immunoprecipitation from activated lymphocytes","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding experiments in primary cells, linked to downstream PLCγ function","pmids":["10556826"],"is_preprint":false},{"year":2000,"finding":"The Itk pleckstrin homology (PH) domain directs constitutive association with buoyant membrane rafts (primary sites of TCR activation) enriched in Lck and LAT. Deficiency of PTEN in Jurkat cells leads to elevated PI-3,4,5-P₃ at the plasma membrane, causing constitutive membrane localization of Itk and hyperresponsiveness to TCR stimulation. PTEN re-expression or PI3K inhibition redistributes Itk to the cytosol and normalizes signaling.","method":"Subcellular fractionation, Western blotting, PI3K inhibitor treatment, PTEN re-expression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — direct localization experiments with functional consequence, multiple orthogonal methods","pmids":["10958690"],"is_preprint":false},{"year":2000,"finding":"Itk forms multivalent interactions with the TCR-proximal signaling complex: (1) its PH domain inositide-binding pocket recruits Itk to buoyant membrane rafts where Lck and LAT reside, enabling transphosphorylation; (2) the proline-rich region binds Grb2 and LAT; (3) SH3 and SH2 domains cooperatively interact with Syk-phosphorylated SLP-76. Kinase-inactive Itk antagonizes SLP-76-dependent NF-AT activation in a PH/proline-rich/SH2-dependent manner.","method":"Co-immunoprecipitation, in vitro binding assays, dominant-negative Itk constructs, NF-AT reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, cooperative domain interactions mapped, functional readout with NF-AT reporter","pmids":["10636929"],"is_preprint":false},{"year":2002,"finding":"The peptidyl-prolyl isomerase cyclophilin A (CypA) inhibits Itk catalytic activity through its isomerase activity. NMR structural studies combined with mutagenesis reveal a proline-dependent conformational switch within the Itk SH2 domain that regulates substrate recognition and mediates interactions with the CypA active site. CypA and Itk form a stable complex in Jurkat T cells that is disrupted by cyclosporin A treatment, and phosphorylation of Itk and PLCγ1 is increased following cyclosporin A treatment.","method":"NMR structural analysis, mutational analysis, co-immunoprecipitation from Jurkat T cells, cyclosporin A treatment, kinase activity assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with mutagenesis and cell-based validation, mechanistically connects CypA isomerase activity to Itk regulation","pmids":["11830645"],"is_preprint":false},{"year":2004,"finding":"Two selective small-molecule inhibitors of Itk (BMS-488516 and BMS-509744) potently inhibit Itk kinase activity and block TCR-induced PLCγ1 tyrosine phosphorylation, calcium mobilization, IL-2 secretion, and T-cell proliferation in vitro in human and mouse cells. BMS-509744 significantly diminishes lung inflammation in a mouse model of ovalbumin-induced allergic asthma, validating Itk as a therapeutic target for Th2-mediated inflammatory diseases.","method":"In vitro kinase assay, calcium mobilization assay, cytokine ELISA, T-cell proliferation assay, murine ovalbumin asthma model","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 2 — selective inhibitors with multiple in vitro and in vivo readouts, mechanistically links Itk to PLCγ1 signaling and Th2 inflammation","pmids":["15323564"],"is_preprint":false},{"year":2005,"finding":"Itk has a kinase-independent scaffolding function in TCR-induced actin polarization: Itk is constitutively associated with the Vav guanine nucleotide exchange factor, and loss of Itk (by siRNA) reduces Vav recruitment to the antigen contact site and disrupts actin polarization. Both wild-type and kinase-inactive Itk rescue actin polarization defects, but Itk with mutations in the PH or SH2 domains cannot. Membrane-targeted Vav (Vav-CAAX) rescues the Itk siRNA phenotype.","method":"siRNA knockdown, re-expression of wild-type and mutant Itk, co-immunoprecipitation, actin polarization imaging, Vav-CAAX rescue","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including genetic rescue and domain mutants, defines scaffolding vs. kinase functions","pmids":["15661896"],"is_preprint":false},{"year":2007,"finding":"SLP-76 not only recruits ITK but also directly maintains ITK kinase activity: the SLP-76/ITK complex interaction is required for both initiation and maintenance of ITK kinase activity, enabling ITK to phosphorylate PLCγ1. This places SLP-76 as more than a neutral adaptor — it actively sustains ITK catalytic function for downstream TCR-stimulated Ca²⁺ mobilization.","method":"Biochemical analysis of SLP-76/ITK complex, kinase activity assays","journal":"Science's STKE","confidence":"Medium","confidence_rationale":"Tier 3 — review/synthesis with mechanistic model supported by cited biochemical data, single source","pmids":["17652306"],"is_preprint":false},{"year":2009,"finding":"ITK is required for Th2 cytokine production (IL-4, IL-5, IL-13), actin reorganization, PLCγ activation, calcium mobilization, and NFAT transcription factor activation downstream of TCR, CD28, CD2, CXCR4, and FcεR signaling in T cells, NKT cells, and mast cells.","method":"Genetic Itk knockout studies, pharmacological inhibition studies reviewed","journal":"Current topics in medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — synthesizes multiple KO and pharmacological studies; reviewed evidence, not primary data","pmids":["19689375"],"is_preprint":false},{"year":2009,"finding":"In the absence of Itk (and Rlk), TCR signaling is impaired with defects in MAPK activation, Ca²⁺ mobilization, and actin polymerization. Itk and Rlk regulate the development of conventional vs. innate CD4⁺ and CD8⁺ T-cell lineages; Itk-deficient mice show altered NKT and γδ T-cell populations, indicating signaling strength via Itk determines conventional versus innate lymphocyte lineage commitment.","method":"Genetic knockout mouse models (Itk⁻/⁻, Rlk⁻/⁻Itk⁻/⁻), T-cell subset phenotyping","journal":"Immunological reviews","confidence":"High","confidence_rationale":"Tier 2 — multiple KO models with defined developmental phenotypes, replicated across studies","pmids":["19290924"],"is_preprint":false},{"year":2009,"finding":"Homozygous missense mutation R335W in the SH2 domain of ITK causes fatal EBV-associated lymphoproliferative disease in two girls. The R335W mutation destabilizes the ITK SH2 domain (in silico modeling) and renders the protein nearly undetectable by Western blot when expressed in 293T cells, indicating protein instability. Patients show NKT cell absence and high eomesodermin in CD8⁺ cells, phenocopying murine Itk deficiency.","method":"SNP array linkage analysis, whole-exome sequencing, in silico protein modeling, Western blot of mutant ITK in 293T cells, flow cytometric immunophenotyping","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — human genetics linked to protein instability with structural prediction and cell-based protein expression data; multiple orthogonal methods","pmids":["19425169"],"is_preprint":false},{"year":2010,"finding":"ITK functions downstream of the TCR to regulate phospholipase C-gamma (PLCγ), with its kinase activity, domain interactions (PH, SH3, SH2, kinase domain), and substrate recognition mechanisms established. ITK controls development of conventional versus innate αβ and γδ T-cell subsets, and regulates effector T-cell differentiation and cytokine gene expression.","method":"Reviewed crystallographic structures, enzymatic studies, genetic models","journal":"Cold Spring Harbor perspectives in biology","confidence":"High","confidence_rationale":"Tier 1–2 — synthesis of multiple structural and genetic studies across labs, highly cited review","pmids":["20519342"],"is_preprint":false},{"year":2010,"finding":"The ITK-SYK fusion kinase (from chromosomal translocation t(5;9)(q33;q22) in peripheral T cell lymphoma) constitutively associates with lipid rafts in T cells and drives antigen-independent phosphorylation of TCR-proximal proteins, activating downstream pathways mimicking TCR ligation (CD69 upregulation, IL-2 production, thymocyte deletion, peripheral T-cell activation). Conditional expression of ITK-SYK in mice induces highly malignant peripheral T cell lymphomas with 100% penetrance.","method":"Conditional transgenic mouse model, biochemical fractionation (lipid rafts), phosphoprotein analysis, T-cell activation assays, in vivo lymphoma model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro and in vivo methods, 100% penetrant mouse model establishes oncogenic mechanism","pmids":["20439541"],"is_preprint":false},{"year":2011,"finding":"Itk is required for the development of invariant NKT αβ cells and a smaller population of NKT-like γδ T cells; Itk-regulated signaling pathways produce different developmental outcomes (conventional vs. innate lineage) in these cell subsets, suggesting the same Itk-regulated TCR signaling pathway is interpreted differently depending on cellular context.","method":"Itk genetic knockout mouse models, T-cell subset flow cytometric analysis","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — KO model with defined phenotypic readout; mechanistic interpretation is inferential","pmids":["21362141"],"is_preprint":false},{"year":2012,"finding":"Loss-of-function mutations in ITK distributed across the entire protein (missense R29H; nonsense/indel D500T,F501L,M503X) cause EBV-associated lymphoproliferative disorders. Wild-type ITK but not mutants rescues defective calcium flux in murine Itk⁻/⁻ T cells. The R29H mutation in the PH domain dramatically reduces binding to phosphatidylinositol monophosphates (PI(3)P, PI(4)P, PI(5)P) and higher-order PIP species. Mutations reduce ITK protein half-life by 25–69% compared to wild-type (t½ = 107 min).","method":"Calcium flux rescue assay in murine Itk⁻/⁻ T cells, pulse-chase protein stability assay, PH domain phosphoinositide binding assay","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical assays (Ca²⁺ rescue, PH binding, pulse-chase), maps mutations to PH-domain phosphoinositide binding function","pmids":["22289921"],"is_preprint":false},{"year":2013,"finding":"CD28-activated ITK specifically licenses autoreactive T cells to traffic from secondary lymphoid organs into target tissues to mount destructive autoimmune responses. Concurrent ablation of ITK in Ctla4⁻/⁻ mice blocks tissue infiltration by self-reactive T cells without preventing their activation or proliferation in lymphoid organs. ITK inhibitors phenocopy the null mutant and prevent pancreatic islet infiltration by diabetogenic T cells.","method":"Genetic double-knockout (Itk⁻/⁻;Ctla4⁻/⁻) mice, adoptive transfer, ITK inhibitor treatment, pancreatic islet histology","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (double KO) plus pharmacological validation in disease models, defines ITK role in T-cell trafficking vs. activation","pmids":["24270545"],"is_preprint":false},{"year":2015,"finding":"ITK inhibitor PRN694 (selective covalent inhibitor of ITK and RLK) blocks Th1 and Th17 differentiation and cytokine production in vitro. In a T-cell adoptive transfer colitis model, in vivo PRN694 administration markedly reduces disease progression, T-cell infiltration into the intestinal lamina propria, IFN-γ production, and P-selectin binding and CXCL11/CCL20-directed migration of Th1/Th17 cells.","method":"In vitro Th polarization assay, adoptive transfer colitis model, flow cytometry, cytokine ELISA, migration assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — selective covalent inhibitor with multiple in vitro and in vivo readouts linking ITK+RLK activity to Th1/Th17 differentiation and migration","pmids":["26466958"],"is_preprint":false},{"year":2015,"finding":"Itk signaling promotes experimental autoimmune encephalomyelitis (EAE): Itk⁻/⁻ mice show reduced disease severity, and adoptive transfer of Itk⁻/⁻ CD4⁺ T cells produces lower disease severity in T cell-deficient recipients. Itk⁻/⁻ CD4⁺ T cells show defective response to myelin antigen, displacement of filamentous actin from the CD4 co-receptor, impaired transmigration across brain endothelial barriers, and reduced Th1/Th17 cytokine production with skewed Teff/Treg ratios.","method":"KO mouse model, adoptive transfer, EAE induction, in vitro transendothelial migration assay, actin imaging, cytokine measurement","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — KO plus adoptive transfer (epistasis), mechanistically links Itk to actin dynamics, CNS transmigration, and cytokine production","pmids":["25568116"],"is_preprint":false},{"year":2017,"finding":"ITK kinase activity is required for TCR-induced development of Type 1 regulatory T (Tr1) cells in various organs and mucosal tissues during parasitic and viral infections. Downstream of ITK, Ras activity is responsible for Tr1 cell induction: constitutively active HRas rescues IRF4 expression and Tr1 cell differentiation in Itk⁻/⁻ cells. The transcription factor IRF4 mediates ITK's effect on Tr1 cell differentiation, as IRF4 overexpression restores Tr1 development and suppressive function of Itk-deficient cells.","method":"Itk⁻/⁻ mouse model, constitutively active HRas rescue, IRF4 overexpression rescue, in vivo infection models, flow cytometry","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (KO + constitutively active Ras rescue + IRF4 rescue), multiple in vivo contexts","pmids":["28635957"],"is_preprint":false},{"year":2019,"finding":"Both genetic loss-of-function (novel ITK mutation) and chemical inhibition of ITK (ibrutinib) result in reduced Th17 generation and IL-17A/IL-22/GM-CSF production in humans, with reciprocally increased IFN-γ (Th1) production. ITK deficiency in a human patient also reduces peripheral ILC2 and ILC3 populations. IBrutinib blocks Th17 generation and augments FoxP3 expression at low doses in Treg cultures.","method":"Whole exome sequencing, flow cytometry, cytokine measurement, ibrutinib pharmacological inhibition of ex vivo human T cells","journal":"Journal of clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — human genetic loss-of-function corroborated by pharmacological inhibition with orthogonal readouts in human cells","pmids":["31025232"],"is_preprint":false},{"year":2020,"finding":"ITK signals downstream of TCR differentially control effector T-cell differentiation: the Ras/MAPK pathway downstream of ITK controls TH17, Foxp3⁺ Treg, and Tr1 cell fate decisions, supporting a model in which ITK signaling strength controls a T-cell effector differentiation decision point.","method":"Genetic KO studies, constitutively active Ras rescue, IRF4 expression analysis (reviewed mechanistic findings)","journal":"Biochemical Society transactions","confidence":"Medium","confidence_rationale":"Tier 2 — synthesizes multiple primary experimental findings; review article, not primary data","pmids":["32049330"],"is_preprint":false}],"current_model":"ITK (IL-2-inducible T-cell kinase), a Tec-family non-receptor tyrosine kinase predominantly expressed in T cells, is activated downstream of TCR stimulation via Lck-mediated transphosphorylation of its activation-loop Tyr511, with membrane recruitment driven by PI3K-generated phosphoinositides binding its PH domain; once activated and assembled into a multivalent complex with SLP-76, LAT, and Grb2 through cooperative SH3/SH2/PH domain interactions, ITK phosphorylates PLCγ1 to drive Ca²⁺ mobilization and NFAT activation, while also performing kinase-independent scaffolding of Vav to regulate actin polarization; ITK activity is negatively regulated by an intramolecular SH3–proline-rich region interaction and by cyclophilin A-mediated prolyl isomerization of the SH2 domain, and is essential for Th2/Th17 cytokine production, conventional vs. innate T-cell lineage commitment, Tr1 cell development (via Ras/IRF4), and autoreactive T-cell trafficking to target tissues, with loss-of-function mutations causing fatal EBV-associated lymphoproliferation in humans."},"narrative":{"teleology":[{"year":1995,"claim":"The identification that Gβγ subunits stimulate ITK kinase activity raised the possibility that ITK integrates signals from heterotrimeric G proteins in addition to receptor tyrosine kinases.","evidence":"Co-transfection and in vitro reconstitution with purified bovine brain Gβγ subunits and immunoprecipitated ITK","pmids":["7567982"],"confidence":"Medium","gaps":["Single-lab finding not independently replicated","Physiological relevance of Gβγ–ITK coupling in primary T cells not established","No identification of upstream GPCR"]},{"year":1996,"claim":"Mapping the SH3 domain interactome (Sam68, WASP, Grb2, Cbl, Fyn) established ITK as a multi-partner signaling hub whose SH3 domain engages distinct proline-rich effectors upon TCR stimulation.","evidence":"Phage display motif definition and SH3 pulldown from TCR-stimulated Jurkat lysates","pmids":["8810341"],"confidence":"High","gaps":["Functional consequence of each individual SH3 interaction not dissected","Relative affinities and competitive binding in vivo unknown"]},{"year":1997,"claim":"Three foundational discoveries resolved ITK activation and autoinhibition: NMR revealed the first intramolecular SH3–proline-rich autoinhibitory interaction in a Tec kinase; reconstitution showed Lck transphosphorylates Tyr511 to activate ITK; and Itk-knockout mice demonstrated a non-redundant requirement for optimal antiviral CTL responses.","evidence":"Multidimensional NMR structure with competitive binding assays; baculovirus co-expression with Y511F mutagenesis and in vitro kinase assay; Itk⁻/⁻ mice with LCMV/vaccinia/VSV infection and IL-2 rescue","pmids":["8985255","9312162","9311799"],"confidence":"High","gaps":["Full-length structural model of autoinhibited ITK not available","Whether Lck is the sole activating kinase in vivo undetermined","Mechanism by which ITK loss reduces CTL responses beyond IL-2 signaling not resolved"]},{"year":1999,"claim":"The demonstration that ITK's SH2 domain selectively binds phospho-SLP-76 linked ITK recruitment to the adaptor scaffold required for PLCγ phosphorylation and Ca²⁺ mobilization.","evidence":"SH2 domain binding assays and co-immunoprecipitation from activated T-cell lysates","pmids":["10556826"],"confidence":"High","gaps":["Stoichiometry and dynamics of the ITK–SLP-76 complex in living cells not measured","Contribution of other SLP-76-binding kinases not delineated"]},{"year":2000,"claim":"Membrane recruitment was mechanistically resolved: the PH domain targets ITK to PIP₃-enriched lipid rafts containing Lck and LAT, and PTEN opposes this localization—establishing PI3K/PTEN as upstream regulators of ITK spatial activation. Concurrently, cooperative multivalent interactions (PH–PIP₃, proline-rich–Grb2/LAT, SH3/SH2–SLP-76) were shown to assemble ITK into the TCR signalosome, with kinase-dead ITK acting as a dominant negative for NFAT activation.","evidence":"Subcellular fractionation with PTEN re-expression and PI3K inhibition; co-IP and in vitro binding with domain mutants and NFAT reporter assay","pmids":["10958690","10636929"],"confidence":"High","gaps":["Quantitative contribution of each multivalent interaction to complex stability unmeasured","Real-time imaging of ITK membrane dynamics not performed"]},{"year":2002,"claim":"The discovery that cyclophilin A inhibits ITK through prolyl isomerization of the SH2 domain introduced a novel post-translational regulatory mechanism and provided an unexpected link between ITK regulation and cyclosporin A pharmacology.","evidence":"NMR structural analysis of the SH2 proline switch, co-IP from Jurkat cells, cyclosporin A disruption of CypA–ITK complex with increased PLCγ1 phosphorylation","pmids":["11830645"],"confidence":"High","gaps":["In vivo contribution of CypA to ITK regulation versus calcineurin inhibition by cyclosporin A not separated","Whether other peptidyl-prolyl isomerases regulate ITK is unknown"]},{"year":2005,"claim":"Separation of kinase-dependent and kinase-independent functions was achieved: ITK scaffolds Vav recruitment to the immunological synapse via PH and SH2 domains to direct actin polarization independently of its catalytic activity.","evidence":"siRNA knockdown with rescue by wild-type versus kinase-dead and domain-mutant ITK constructs; Vav-CAAX rescue of actin polarization","pmids":["15661896"],"confidence":"High","gaps":["How ITK's scaffolding and kinase functions are temporally coordinated is unresolved","Structural basis of the constitutive ITK–Vav interaction undefined"]},{"year":2009,"claim":"ITK was established as a master regulator of T-cell lineage fate: Itk⁻/⁻ mice show expansion of innate-like T cells (NKT, γδ) at the expense of conventional αβ T cells, indicating that ITK-dependent TCR signal strength determines the conventional versus innate lineage decision. Simultaneously, human genetics proved ITK essential for EBV control, as homozygous R335W (SH2 domain) caused fatal lymphoproliferative disease with absent NKT cells.","evidence":"Itk⁻/⁻ and Rlk⁻/⁻Itk⁻/⁻ KO mouse models with flow cytometric T-cell subset analysis; human exome sequencing, in silico modeling, Western blot of mutant protein in 293T cells, immunophenotyping","pmids":["19290924","19425169"],"confidence":"High","gaps":["Molecular threshold of TCR signal strength that toggles lineage fate not quantified","Whether ITK deficiency-related lymphoproliferation reflects solely NKT cell absence or additional immune defects is unclear"]},{"year":2012,"claim":"Additional human loss-of-function mutations mapped across ITK (PH domain R29H; kinase domain truncations) confirmed genotype–phenotype correlations: the R29H mutation specifically ablates PH domain phosphoinositide binding and all mutations reduce protein half-life, directly connecting lipid-binding-driven membrane recruitment and protein stability to human disease.","evidence":"Calcium flux rescue in murine Itk⁻/⁻ T cells, pulse-chase protein stability assay, PH domain–phosphoinositide binding assay","pmids":["22289921"],"confidence":"High","gaps":["Crystal structure of R29H PH domain not determined","Whether reduced half-life is due to misfolding or active degradation pathway not identified"]},{"year":2013,"claim":"A non-redundant role for ITK in licensing autoreactive T-cell tissue infiltration (distinct from activation/proliferation) was demonstrated: ITK ablation in Ctla4⁻/⁻ mice blocks self-reactive T-cell egress from lymphoid organs without suppressing their activation, positioning ITK as a specific target for autoimmune tissue destruction.","evidence":"Itk⁻/⁻;Ctla4⁻/⁻ double-KO mice, adoptive transfer, ITK inhibitor treatment, pancreatic islet histology","pmids":["24270545"],"confidence":"High","gaps":["Molecular mechanism by which ITK controls tissue-homing molecule expression not fully defined","Whether this trafficking role is kinase-dependent or scaffolding-dependent is unknown"]},{"year":2015,"claim":"Pharmacological and genetic studies converged to show ITK controls Th17 differentiation and T-cell transendothelial migration: selective covalent ITK/RLK inhibitor PRN694 blocked Th1/Th17 cytokines and reduced colitis severity, while Itk⁻/⁻ CD4⁺ T cells showed impaired transmigration across brain endothelial barriers and reduced EAE severity with altered Teff/Treg ratios.","evidence":"In vitro Th polarization, adoptive transfer colitis model, PRN694 treatment; Itk⁻/⁻ EAE model with in vitro transendothelial migration assay and actin imaging","pmids":["26466958","25568116"],"confidence":"High","gaps":["Relative contributions of ITK versus RLK to PRN694 efficacy not separated","Actin–CD4 coreceptor displacement mechanism not molecularly defined"]},{"year":2017,"claim":"The downstream signaling axis was extended: ITK kinase activity drives Tr1 cell development through Ras-dependent IRF4 expression, as constitutively active HRas and IRF4 overexpression each rescue Tr1 differentiation in Itk⁻/⁻ cells across parasitic and viral infection models.","evidence":"Itk⁻/⁻ mice with constitutively active HRas or IRF4 rescue, in vivo infection models, flow cytometry","pmids":["28635957"],"confidence":"High","gaps":["Direct biochemical link between ITK kinase activity and Ras activation not established","Whether ITK–Ras–IRF4 axis operates in human Tr1 cells not confirmed"]},{"year":2019,"claim":"Human validation confirmed ITK's role in Th17 biology: a novel ITK loss-of-function patient and ibrutinib treatment both reduced Th17 generation and IL-17A/IL-22/GM-CSF production while increasing IFN-γ, and reduced ILC2/ILC3 populations, extending ITK function beyond adaptive T cells to innate lymphoid cells.","evidence":"Human exome sequencing, ex vivo ibrutinib treatment of human T cells, flow cytometry, cytokine measurement","pmids":["31025232"],"confidence":"High","gaps":["Ibrutinib also inhibits BTK; ITK-selective effects in human cells require confirmation with cleaner tools","Whether ILC2/ILC3 reduction is cell-intrinsic or secondary to T-cell dysfunction unclear"]},{"year":null,"claim":"Key unresolved questions include the full-length structure of autoinhibited ITK, the molecular mechanism by which ITK controls tissue-homing programs independently of proliferative signals, the direct biochemical connection between ITK and Ras activation, and whether kinase-dependent versus scaffolding functions can be pharmacologically separated for therapeutic benefit.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length autoinhibited structure resolved","Kinase-dependent vs. scaffolding functions not pharmacologically separable yet","ITK–Ras link lacks direct biochemical reconstitution"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,9,15]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[10,7]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[6,18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,7,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,9,12,13,14,19,20,22,23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,7,8,9,15]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[13,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[14,16,18]}],"complexes":[],"partners":["LCK","SLP76","PLCG1","VAV1","GRB2","PPIA","LAT","WASP"],"other_free_text":[]},"mechanistic_narrative":"ITK is a Tec-family non-receptor tyrosine kinase that serves as a central integrator of T-cell receptor (TCR) signaling, coupling antigen recognition to downstream effector programs including calcium mobilization, cytokine production, actin polarization, and T-cell differentiation. Activated by Lck-mediated transphosphorylation of Tyr511 upon PI3K-dependent PH-domain-mediated membrane recruitment, ITK assembles into a multivalent signaling complex with SLP-76, LAT, and Grb2 through cooperative SH3/SH2/PH domain interactions and phosphorylates PLCγ1 to drive Ca²⁺ flux and NFAT activation; its catalytic activity is negatively regulated by intramolecular SH3–proline-rich autoinhibition and cyclophilin A-mediated prolyl isomerization of the SH2 domain [PMID:9312162, PMID:10636929, PMID:8985255, PMID:11830645]. ITK also performs a kinase-independent scaffolding function by constitutively associating with Vav to direct actin polarization at the immunological synapse, and controls conventional versus innate T-cell lineage commitment, Th2/Th17 cytokine production, Tr1 cell development via the Ras/IRF4 axis, and autoreactive T-cell trafficking to target tissues [PMID:15661896, PMID:19290924, PMID:28635957, PMID:24270545]. Loss-of-function mutations in ITK cause fatal EBV-associated lymphoproliferative disease in humans, with absent NKT cells phenocopying the murine knockout [PMID:19425169, PMID:22289921]."},"prefetch_data":{"uniprot":{"accession":"Q08881","full_name":"Tyrosine-protein kinase ITK/TSK","aliases":["Interleukin-2-inducible T-cell kinase","IL-2-inducible T-cell kinase","Kinase EMT","T-cell-specific kinase","Tyrosine-protein kinase Lyk"],"length_aa":620,"mass_kda":71.8,"function":"Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. Once activated, phosphorylates PLCG1, leading to the activation of this lipase and subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Phosphorylates 2 essential adapter proteins: the linker for activation of T-cells/LAT protein and LCP2. Then, a large number of signaling molecules such as VAV1 are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation (PubMed:12186560, PubMed:12682224, PubMed:21725281). Required for TCR-mediated calcium response in gamma-delta T-cells, may also be involved in the modulation of the transcriptomic signature in the Vgamma2-positive subset of immature gamma-delta T-cells (By similarity). Phosphorylates TBX21 at 'Tyr-530' and mediates its interaction with GATA3 (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q08881/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ITK","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ITK","total_profiled":1310},"omim":[{"mim_id":"615758","title":"IMMUNODEFICIENCY 22; IMD22","url":"https://www.omim.org/entry/615758"},{"mim_id":"613011","title":"LYMPHOPROLIFERATIVE SYNDROME 1; LPFS1","url":"https://www.omim.org/entry/613011"},{"mim_id":"608232","title":"LEUKEMIA, CHRONIC MYELOID; CML","url":"https://www.omim.org/entry/608232"},{"mim_id":"607762","title":"KIRRE-LIKE NEPHRIN FAMILY ADHESION MOLECULE 2; KIRREL2","url":"https://www.omim.org/entry/607762"},{"mim_id":"607761","title":"KIRRE-LIKE NEPHRIN FAMILY ADHESION MOLECULE 3; KIRREL3","url":"https://www.omim.org/entry/607761"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":53.6}],"url":"https://www.proteinatlas.org/search/ITK"},"hgnc":{"alias_symbol":["EMT","PSCTK2","LYK"],"prev_symbol":[]},"alphafold":{"accession":"Q08881","domains":[{"cath_id":"2.30.29.30","chopping":"6-146","consensus_level":"high","plddt":88.4175,"start":6,"end":146},{"cath_id":"2.30.30.40","chopping":"176-229","consensus_level":"high","plddt":88.453,"start":176,"end":229},{"cath_id":"3.30.505.10","chopping":"241-338","consensus_level":"high","plddt":84.6316,"start":241,"end":338},{"cath_id":"3.30.200.20","chopping":"361-437","consensus_level":"high","plddt":82.9173,"start":361,"end":437},{"cath_id":"1.10.510.10","chopping":"442-619","consensus_level":"high","plddt":89.5729,"start":442,"end":619}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q08881","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q08881-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q08881-F1-predicted_aligned_error_v6.png","plddt_mean":84.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ITK","jax_strain_url":"https://www.jax.org/strain/search?query=ITK"},"sequence":{"accession":"Q08881","fasta_url":"https://rest.uniprot.org/uniprotkb/Q08881.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q08881/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q08881"}},"corpus_meta":[{"pmid":"27368099","id":"PMC_27368099","title":"EMT: 2016.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/27368099","citation_count":3694,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29326430","id":"PMC_29326430","title":"EMT in cancer.","date":"2018","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29326430","citation_count":1594,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29670281","id":"PMC_29670281","title":"Identification of the tumour transition states occurring during EMT.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29670281","citation_count":1139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24168186","id":"PMC_24168186","title":"The Role of Snail in EMT and Tumorigenesis.","date":"2013","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/24168186","citation_count":739,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27878502","id":"PMC_27878502","title":"EMT, cell plasticity and metastasis.","date":"2016","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27878502","citation_count":682,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24954536","id":"PMC_24954536","title":"KRAS and YAP1 converge to regulate EMT and tumor survival.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/24954536","citation_count":650,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22945800","id":"PMC_22945800","title":"EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness.","date":"2012","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/22945800","citation_count":441,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22710176","id":"PMC_22710176","title":"Regulation of EMT by TGFβ in cancer.","date":"2012","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/22710176","citation_count":429,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26828526","id":"PMC_26828526","title":"Role of EMT in Metastasis and Therapy Resistance.","date":"2016","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26828526","citation_count":404,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27371787","id":"PMC_27371787","title":"Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe?","date":"2016","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27371787","citation_count":399,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27136592","id":"PMC_27136592","title":"Tumor Budding: The Name is EMT. Partial EMT.","date":"2016","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27136592","citation_count":391,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28834698","id":"PMC_28834698","title":"EMT: Mechanisms and therapeutic implications.","date":"2017","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28834698","citation_count":378,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20943648","id":"PMC_20943648","title":"The epithelial-mesenchymal transition (EMT) phenomenon.","date":"2010","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20943648","citation_count":346,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34201858","id":"PMC_34201858","title":"Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34201858","citation_count":332,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20012924","id":"PMC_20012924","title":"Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.","date":"2009","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20012924","citation_count":325,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34638469","id":"PMC_34638469","title":"Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34638469","citation_count":318,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17211838","id":"PMC_17211838","title":"Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17211838","citation_count":281,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23604123","id":"PMC_23604123","title":"Multilayer control of the EMT master regulators.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23604123","citation_count":274,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20041844","id":"PMC_20041844","title":"The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness.","date":"2010","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/20041844","citation_count":271,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21665887","id":"PMC_21665887","title":"The EMT regulator slug and lung carcinogenesis.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21665887","citation_count":270,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15846061","id":"PMC_15846061","title":"The epithelial-mesenchymal transition (EMT) and colorectal cancer progression.","date":"2005","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15846061","citation_count":257,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28669750","id":"PMC_28669750","title":"EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET.","date":"2017","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28669750","citation_count":238,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30021582","id":"PMC_30021582","title":"Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology.","date":"2018","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/30021582","citation_count":230,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20168078","id":"PMC_20168078","title":"Snail: More than EMT.","date":"2010","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/20168078","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10636929","id":"PMC_10636929","title":"Biochemical interactions integrating Itk with the T cell receptor-initiated signaling cascade.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10636929","citation_count":215,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20519342","id":"PMC_20519342","title":"T-cell signaling regulated by the Tec family kinase, Itk.","date":"2010","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20519342","citation_count":213,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30723913","id":"PMC_30723913","title":"The basics of epithelial-mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30723913","citation_count":207,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31401189","id":"PMC_31401189","title":"Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process.","date":"2019","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/31401189","citation_count":206,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32503307","id":"PMC_32503307","title":"Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32503307","citation_count":203,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32358524","id":"PMC_32358524","title":"Context specificity of the EMT transcriptional response.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32358524","citation_count":178,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20659767","id":"PMC_20659767","title":"Cadherins in the human placenta--epithelial-mesenchymal transition (EMT) and placental development.","date":"2010","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/20659767","citation_count":178,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27915969","id":"PMC_27915969","title":"Anoikis and EMT: Lethal \"Liaisons\" during Cancer Progression.","date":"2016","source":"Critical reviews in oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27915969","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30229551","id":"PMC_30229551","title":"Epithelial-Mesenchymal Transition (EMT) and Prostate Cancer.","date":"2018","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/30229551","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28667075","id":"PMC_28667075","title":"AXL-Driven EMT State as a Targetable Conduit in Cancer.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28667075","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33401271","id":"PMC_33401271","title":"Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target.","date":"2021","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/33401271","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31027222","id":"PMC_31027222","title":"Role of Metabolic Reprogramming in Epithelial⁻Mesenchymal Transition (EMT).","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31027222","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25346895","id":"PMC_25346895","title":"Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.","date":"2013","source":"Translational andrology and urology","url":"https://pubmed.ncbi.nlm.nih.gov/25346895","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26506454","id":"PMC_26506454","title":"F-box proteins: Keeping the epithelial-to-mesenchymal transition (EMT) in check.","date":"2015","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/26506454","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23888971","id":"PMC_23888971","title":"Epigenetic regulation of EMT: the Snail story.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/23888971","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15661896","id":"PMC_15661896","title":"Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15661896","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37532929","id":"PMC_37532929","title":"Pharmacological targeting of netrin-1 inhibits EMT in cancer.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37532929","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32047115","id":"PMC_32047115","title":"Reversible EMT and MET mediate amnion remodeling during pregnancy and labor.","date":"2020","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32047115","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15323564","id":"PMC_15323564","title":"Selective Itk inhibitors block T-cell activation and murine lung inflammation.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15323564","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28366557","id":"PMC_28366557","title":"FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28366557","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22733307","id":"PMC_22733307","title":"The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis.","date":"2012","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22733307","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28544151","id":"PMC_28544151","title":"The EMT spectrum and therapeutic opportunities.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28544151","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29674112","id":"PMC_29674112","title":"Cadherin profiling for therapeutic interventions in Epithelial Mesenchymal Transition (EMT) and tumorigenesis.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29674112","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27623213","id":"PMC_27623213","title":"AKT-ions with a TWIST between EMT and MET.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27623213","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28825675","id":"PMC_28825675","title":"Polyphenolic Nutrients in Cancer Chemoprevention and Metastasis: Role of the Epithelial-to-Mesenchymal (EMT) Pathway.","date":"2017","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/28825675","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23261166","id":"PMC_23261166","title":"Emerging roles of PDGF-D in EMT progression during tumorigenesis.","date":"2012","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23261166","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31766144","id":"PMC_31766144","title":"Role of ACTN4 in Tumorigenesis, Metastasis, and EMT.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31766144","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28635957","id":"PMC_28635957","title":"ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28635957","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19290924","id":"PMC_19290924","title":"The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19290924","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34113749","id":"PMC_34113749","title":"The Epithelial-to-Mesenchymal Transition (EMT) in Development and Cancer.","date":"2019","source":"Annual review of cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/34113749","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30042172","id":"PMC_30042172","title":"Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT.","date":"2018","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30042172","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26818837","id":"PMC_26818837","title":"Overexpression of HMGA2 promotes tongue cancer metastasis through EMT pathway.","date":"2016","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26818837","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34680444","id":"PMC_34680444","title":"Cadherin Expression and EMT: A Focus on Gliomas.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/34680444","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27279361","id":"PMC_27279361","title":"The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer.","date":"2016","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/27279361","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23672610","id":"PMC_23672610","title":"Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.","date":"2013","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23672610","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32353468","id":"PMC_32353468","title":"Hypoxia-induced lncRNA RP11-390F4.3 promotes epithelial-mesenchymal transition (EMT) and metastasis through upregulating EMT regulators.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32353468","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24168184","id":"PMC_24168184","title":"Regulation of EMT by KLF4 in gastrointestinal cancer.","date":"2013","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/24168184","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32521264","id":"PMC_32521264","title":"PRMT1-p53 Pathway Controls Epicardial EMT and Invasion.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32521264","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35604626","id":"PMC_35604626","title":"The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer.","date":"2022","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35604626","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19689375","id":"PMC_19689375","title":"ITK inhibitors in inflammation and immune-mediated disorders.","date":"2009","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19689375","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34324787","id":"PMC_34324787","title":"Calcium signaling induces a partial EMT.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/34324787","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32808093","id":"PMC_32808093","title":"Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.","date":"2020","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/32808093","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18591967","id":"PMC_18591967","title":"Breaking down EMT.","date":"2008","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18591967","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35203300","id":"PMC_35203300","title":"Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35203300","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25634102","id":"PMC_25634102","title":"Catabolic metabolism during cancer EMT.","date":"2015","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/25634102","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23947008","id":"PMC_23947008","title":"Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy.","date":"2013","source":"Investigacion clinica","url":"https://pubmed.ncbi.nlm.nih.gov/23947008","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25356753","id":"PMC_25356753","title":"Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25356753","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34421348","id":"PMC_34421348","title":"Partial EMT in Squamous Cell Carcinoma: A Snapshot.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34421348","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30131448","id":"PMC_30131448","title":"p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30131448","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25678598","id":"PMC_25678598","title":"MAPK7 Regulates EMT Features and Modulates the Generation of CTCs.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25678598","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27900516","id":"PMC_27900516","title":"Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT).","date":"2016","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27900516","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9311799","id":"PMC_9311799","title":"Antiviral immune responses in Itk-deficient mice.","date":"1997","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9311799","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33746610","id":"PMC_33746610","title":"Unraveling the Molecular Nexus between GPCRs, ERS, and EMT.","date":"2021","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33746610","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31025232","id":"PMC_31025232","title":"Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31025232","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38092761","id":"PMC_38092761","title":"Morphological and cytoskeleton changes in cells after EMT.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38092761","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24270545","id":"PMC_24270545","title":"CD28 and ITK signals regulate autoreactive T cell trafficking.","date":"2013","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24270545","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36932397","id":"PMC_36932397","title":"EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36932397","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25568116","id":"PMC_25568116","title":"Itk signals promote neuroinflammation by regulating CD4+ T-cell activation and trafficking.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25568116","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32491994","id":"PMC_32491994","title":"UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32491994","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30247800","id":"PMC_30247800","title":"NEK4 kinase regulates EMT to promote lung cancer metastasis.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30247800","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27590006","id":"PMC_27590006","title":"MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer.","date":"2016","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/27590006","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28681541","id":"PMC_28681541","title":"MRTFs- master regulators of EMT.","date":"2017","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/28681541","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14690517","id":"PMC_14690517","title":"The localisation of the extraneuronal monoamine transporter (EMT) in rat brain.","date":"2004","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14690517","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31071975","id":"PMC_31071975","title":"UPR: An Upstream Signal to EMT Induction in Cancer.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31071975","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35020133","id":"PMC_35020133","title":"EMT and Inflammation: Crossroads in HCC.","date":"2022","source":"Journal of gastrointestinal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35020133","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33436008","id":"PMC_33436008","title":"CDCA4 suppresses epithelial-mesenchymal transtion (EMT) and metastasis in Non-small cell lung cancer through modulating autophagy.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33436008","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26466958","id":"PMC_26466958","title":"A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26466958","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25486362","id":"PMC_25486362","title":"Autophagy functions on EMT in gastrulation of avian embryo.","date":"2014","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25486362","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22554796","id":"PMC_22554796","title":"On translational regulation and EMT.","date":"2012","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/22554796","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34368657","id":"PMC_34368657","title":"Targeting ITK signaling for T cell-mediated diseases.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34368657","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32353411","id":"PMC_32353411","title":"The role of miR-34c-5p/Notch in epithelial-mesenchymal transition (EMT) in endometriosis.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32353411","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32049330","id":"PMC_32049330","title":"Tuning T helper cell differentiation by ITK.","date":"2020","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/32049330","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37787987","id":"PMC_37787987","title":"Eriocitrin inhibits epithelial-mesenchymal transformation (EMT) in lung adenocarcinoma cells via triggering ferroptosis.","date":"2023","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/37787987","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21362141","id":"PMC_21362141","title":"Tec family kinases: Itk signaling and the development of NKT αβ and γδ T cells.","date":"2011","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21362141","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40362600","id":"PMC_40362600","title":"Molecular Mechanisms Regulating Epithelial Mesenchymal Transition (EMT) to Promote Cancer Progression.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40362600","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17652306","id":"PMC_17652306","title":"Keeping the (kinase) party going: SLP-76 and ITK dance to the beat.","date":"2007","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/17652306","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939624","id":"PMC_22939624","title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939624","citation_count":708,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16273093","id":"PMC_16273093","title":"A quantitative protein interaction network for the ErbB receptors using protein microarrays.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16273093","citation_count":568,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15761153","id":"PMC_15761153","title":"High-throughput mapping of a dynamic signaling network in mammalian cells.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15761153","citation_count":553,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8629002","id":"PMC_8629002","title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8629002","citation_count":391,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10958690","id":"PMC_10958690","title":"Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10958690","citation_count":276,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8630736","id":"PMC_8630736","title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8630736","citation_count":261,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11830645","id":"PMC_11830645","title":"Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11830645","citation_count":234,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8985255","id":"PMC_8985255","title":"Regulatory intramolecular association in a tyrosine kinase of the Tec family.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8985255","citation_count":234,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19425169","id":"PMC_19425169","title":"Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19425169","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10556826","id":"PMC_10556826","title":"Interaction of SLP adaptors with the SH2 domain of Tec family kinases.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10556826","citation_count":198,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15144186","id":"PMC_15144186","title":"Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.","date":"2004","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15144186","citation_count":174,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10022833","id":"PMC_10022833","title":"Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10022833","citation_count":166,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19240061","id":"PMC_19240061","title":"Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling.","date":"2009","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/19240061","citation_count":157,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8810341","id":"PMC_8810341","title":"Identification of Itk/Tsk Src homology 3 domain ligands.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8810341","citation_count":150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9312162","id":"PMC_9312162","title":"Lck phosphorylates the activation loop tyrosine of the Itk kinase domain and activates Itk kinase activity.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9312162","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24658140","id":"PMC_24658140","title":"The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells.","date":"2014","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/24658140","citation_count":131,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11598012","id":"PMC_11598012","title":"PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11598012","citation_count":125,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7567982","id":"PMC_7567982","title":"Activation of Tsk and Btk tyrosine kinases by G protein beta gamma subunits.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7567982","citation_count":122,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20439541","id":"PMC_20439541","title":"The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.","date":"2010","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20439541","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34857952","id":"PMC_34857952","title":"Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34857952","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25402006","id":"PMC_25402006","title":"In silico prediction of physical protein interactions and characterization of interactome orphans.","date":"2014","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/25402006","citation_count":112,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12190313","id":"PMC_12190313","title":"Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.","date":"2002","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12190313","citation_count":110,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30021884","id":"PMC_30021884","title":"Histone Interaction Landscapes Visualized by Crosslinking Mass Spectrometry in Intact Cell Nuclei.","date":"2018","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/30021884","citation_count":101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22289921","id":"PMC_22289921","title":"Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22289921","citation_count":100,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39621,"output_tokens":3940,"usd":0.088982},"stage2":{"model":"claude-opus-4-6","input_tokens":7396,"output_tokens":2826,"usd":0.161445},"total_usd":0.613954,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":52256,"output_tokens":7854,"usd":0.137289},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10595,"output_tokens":3914,"usd":0.226238}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"ITK pleckstrin homology (PH) domain directs constitutive association with buoyant lipid raft membranes enriched in Lck and LAT, which is required for transphosphorylation of ITK. The proline-rich region of ITK binds Grb2 and LAT, and the SH3 and SH2 domains interact cooperatively with Syk-phosphorylated SLP-76. SLP-76 contains a predicted ITK SH2-binding motif and binds full-length ITK in vitro. Kinase-inactive ITK antagonizes SLP-76-dependent NF-AT activation in a manner dependent on the PH domain, proline-rich region, and SH2 domain.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, dominant-negative overexpression, fractionation of lipid raft membranes, NF-AT reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pulldown, Co-IP, reporter assay, fractionation) in single study with functional validation\",\n      \"pmids\": [\"10636929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ITK has a kinase-independent scaffolding function in TCR-induced actin polarization. ITK is constitutively associated with Vav, and loss of ITK expression (via siRNA) reduces Vav recruitment to the immune synapse and disrupts actin polarization without altering gross Vav tyrosine phosphorylation. Re-expression of wild-type or kinase-inactive ITK rescues actin polarization and Vav localization, but ITK mutants lacking functional PH or SH2 domains do not. Membrane-targeted Vav (Vav-CAAX) rescues the ITK-knockdown phenotype, placing ITK upstream of Vav membrane localization.\",\n      \"method\": \"siRNA knockdown, rescue with wild-type and mutant ITK constructs, Co-immunoprecipitation (constitutive ITK-Vav association), confocal imaging of actin polarization, membrane-targeted Vav rescue\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KD + rescue + Co-IP + imaging) with defined cellular phenotype\",\n      \"pmids\": [\"15661896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Selective small-molecule inhibitors of ITK kinase activity (BMS-488516 and BMS-509744) block TCR-induced PLCγ1 tyrosine phosphorylation, calcium mobilization, IL-2 secretion, and T cell proliferation in human and mouse cells in vitro, and suppress IL-2 production and lung inflammation in vivo, demonstrating that ITK kinase activity is required for these downstream signaling events.\",\n      \"method\": \"In vitro kinase inhibition assay, PLCγ1 phosphorylation western blot, calcium flux assay, IL-2 ELISA, T cell proliferation assay, murine ovalbumin asthma model\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay plus multiple functional readouts, confirmed in vivo\",\n      \"pmids\": [\"15323564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SLP-76 forms a complex with ITK and not only acts as a neutral adaptor but directly stimulates and maintains ITK kinase activity, enabling ITK to phosphorylate PLCγ1 at the specific tyrosine required for its activation downstream of TCR stimulation.\",\n      \"method\": \"Biochemical interaction studies, kinase activity assays, phosphorylation assays of PLCγ1\",\n      \"journal\": \"Science's STKE : signal transduction knowledge environment\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review/perspective summarizing biochemical findings; mechanism supported by primary data cited therein\",\n      \"pmids\": [\"17652306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ITK and RLK are required for TCR signaling including MAPK activation, Ca2+ mobilization, and actin polymerization during T cell development. In Itk/Rlk-deficient mice, loss of these kinases shifts T cell development from conventional to innate CD4+ and CD8+ T cell lineages, indicating that TCR signal strength controlled by ITK/RLK determines conventional versus innate lymphocyte lineage commitment.\",\n      \"method\": \"Genetic knockout (Itk-/- and Itk-/-Rlk-/- mice), T cell developmental analysis, signaling assays (MAPK, Ca2+ flux, actin polymerization)\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined developmental phenotype, replicated across multiple studies\",\n      \"pmids\": [\"19290924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ITK mediates TCR-, CD28-, CD2-, CXCR4-, and FcεR-dependent signaling in T cells, and is specifically required for PLCγ activation, actin reorganization, calcium mobilization, NFAT activation, and secretion of Th2 cytokines (IL-4, IL-5, IL-13) and IL-2.\",\n      \"method\": \"Genetic knockout studies (Itk-/- mice), cytokine secretion assays, calcium flux, NFAT reporter assays\",\n      \"journal\": \"Current topics in medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple functional readouts; review synthesizing established findings\",\n      \"pmids\": [\"19689375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ITK functions downstream of the T cell receptor to regulate PLCγ activation and is the predominant Tec kinase in T cells. ITK protein domain interactions (PH, SH3, SH2, kinase domain) govern enzymatic regulation and substrate recognition of PLCγ. ITK also plays distinct roles in development of conventional versus innate T cell lineages including αβ, γδ, and NKT cells, and in Th effector differentiation and cytokine gene expression.\",\n      \"method\": \"Structural studies of ITK domains, genetic knockout analysis, domain mutagenesis, T cell functional assays\",\n      \"journal\": \"Cold Spring Harbor perspectives in biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — comprehensive review with structural and genetic evidence, multiple labs\",\n      \"pmids\": [\"20519342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Itk-deficient mice show reduced primary cytotoxic T lymphocyte responses (2–6-fold reduction) to LCMV, vaccinia virus, and VSV, and delayed clearance of vaccinia virus, demonstrating that Itk is required for optimal antiviral CTL responses but not for B cell antibody responses.\",\n      \"method\": \"Genetic knockout (Itk-/- mice), ex vivo CTL killing assay, viral clearance kinetics, antibody ELISA\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined functional phenotype\",\n      \"pmids\": [\"9311799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Itk signaling is critical for the development of invariant NKT αβ cells and NKT-like γδ T cells, indicating that Itk-regulated TCR signaling is interpreted differently in conventional versus non-conventional T cell lineages to produce distinct developmental outcomes.\",\n      \"method\": \"Genetic knockout (Itk-/- mice), flow cytometry of thymic and peripheral T cell subsets\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined developmental phenotype; review citing primary data\",\n      \"pmids\": [\"21362141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Genetic ablation of ITK in Ctla4-/- mice does not block spontaneous T cell activation or proliferation in lymphoid organs but prevents autoreactive T cell trafficking into peripheral tissues. ITK thus specifically licenses autoreactive T cells to enter tissues. Small-molecule ITK inhibitors phenocopy the null mutant and also prevent pancreatic islet infiltration by diabetogenic T cells.\",\n      \"method\": \"Double knockout mice (Itk-/-; Ctla4-/-), adoptive transfer, T cell trafficking assays, pharmacological ITK inhibition, mouse model of type 1 diabetes (islet infiltration)\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double KO, pharmacological validation, multiple disease models\",\n      \"pmids\": [\"24270545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Itk signaling in CD4+ T cells is required for experimental autoimmune encephalomyelitis (EAE). Itk-/- CD4+ T cells show defective response to myelin antigen due to displacement of filamentous actin from the CD4 co-receptor, resulting in inadequate transmigration across brain endothelial barriers. Itk-/- CD4+ T cells produce less Th1 and Th17 cytokines and show skewed Teff/Treg ratios.\",\n      \"method\": \"Genetic knockout (Itk-/- mice), EAE model, adoptive T cell transfer, actin imaging, in vitro transendothelial migration assay, cytokine ELISA\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + adoptive transfer + mechanistic imaging with defined disease phenotype\",\n      \"pmids\": [\"25568116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A covalent small-molecule inhibitor (PRN694) of ITK and RLK suppresses Th1 and Th17 differentiation and cytokine production in vitro, reduces P-selectin binding by Th1 cells and CXCL11/CCL20-driven migration by Th1/Th17 cells, and markedly reduces disease progression and T cell infiltration into the intestinal lamina propria in a T cell adoptive transfer colitis model in vivo.\",\n      \"method\": \"In vitro Th polarization assays, cytokine ELISA, P-selectin binding assay, chemotaxis assay, T cell adoptive transfer colitis model, flow cytometry\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — selective covalent inhibitor with multiple in vitro functional assays and in vivo disease model\",\n      \"pmids\": [\"26466958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ITK kinase activity is required for TCR-induced development of Type 1 regulatory T (Tr1) cells. Downstream of ITK, Ras activity drives IRF4 expression, which is required for Tr1 cell differentiation and suppressive function. Expression of constitutively active HRas rescues IRF4 expression and Tr1 cell differentiation in Itk-/- cells, and expression of IRF4 restores Tr1 development and function in Itk-deficient cells.\",\n      \"method\": \"Genetic knockout (Itk-/- mice), retroviral rescue with constitutively active HRas and IRF4, Tr1 cell differentiation assays, cytokine production (IL-10), parasitic/viral infection models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + epistasis rescue experiments with defined molecular pathway\",\n      \"pmids\": [\"28635957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss-of-function mutation in human ITK impairs CD3/CD28-induced T cell proliferation, increases T cell apoptosis, reduces Th17-associated cytokine production (IL-17A, IL-22, GM-CSF), and increases IFN-γ production. Pharmacological inhibition of ITK with ibrutinib blocks ex vivo Th17 generation and IL-17A production and augments FOXP3 expression at low doses. ITK deficiency also reduces ILC2 and ILC3 populations.\",\n      \"method\": \"Whole exome sequencing (patient mutation), flow cytometry, proliferation/apoptosis assays, cytokine production assays, ibrutinib pharmacological inhibition\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetic deficiency validated with pharmacological inhibition, multiple functional readouts\",\n      \"pmids\": [\"31025232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ITK signals through the Ras/MAPK pathway to differentially control differentiation of Th17, Foxp3+ Treg, and Tr1 cells, supporting a model whereby ITK controls a key decision point in effector CD4+ T cell differentiation.\",\n      \"method\": \"Genetic knockout, retroviral rescue, T helper differentiation assays, cytokine profiling\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review synthesizing multiple genetic and biochemical experiments from same group\",\n      \"pmids\": [\"32049330\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ITK (IL-2-inducible T cell kinase), a Tec family non-receptor tyrosine kinase predominantly expressed in T cells, is recruited to LAT-nucleated signaling complexes at lipid rafts via its PH domain, where it is transphosphorylated; its SH3 and SH2 domains cooperatively engage SLP-76, which directly activates and maintains ITK kinase activity, enabling ITK to phosphorylate PLCγ1 at the specific tyrosine required for calcium mobilization and NFAT activation; ITK also performs a kinase-independent scaffolding function that positions Vav at the immune synapse for TCR-induced actin polarization; downstream of TCR/ITK, the Ras/IRF4 pathway controls Tr1 cell differentiation, while ITK signals globally tune the Th1/Th2/Th17/Treg balance, regulate conventional versus innate T cell lineage commitment, and license autoreactive T cells to traffic into peripheral tissues.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n- Papers [1]-[24] in retrieved corpus (EMT-related): EXCLUDE (alias collision — \"EMT\" here refers to epithelial-mesenchymal transition, not the gene ITK)\n- Paper [25] PMID:10636929 — KEEP (ITK/Itk Tec kinase)\n- Paper [26] PMID:20519342 — KEEP (ITK review)\n- Paper [40] PMID:15661896 — KEEP (Itk kinase)\n- Paper [43] PMID:15323564 — KEEP (Itk inhibitors)\n- Paper [52] PMID:28635957 — KEEP (ITK signaling)\n- Paper [53] PMID:19290924 — KEEP (Itk T-cell development)\n- Paper [59] PMID:23672610 — KEEP (BTK/ITK inhibitors)\n- Paper [64] PMID:19689375 — KEEP (ITK)\n- Paper [66] PMID:32808093 — KEEP (ITK)\n- Paper [76] PMID:9311799 — KEEP (Itk-deficient mice)\n- Paper [78] PMID:31025232 — KEEP (ITK)\n- Paper [80] PMID:24270545 — KEEP (ITK)\n- Paper [82] PMID:25568116 — KEEP (Itk)\n- Paper [87] PMID:14690517 — EXCLUDE (EMT = extraneuronal monoamine transporter, alias collision)\n- Paper [91] PMID:26466958 — KEEP (ITK/RLK inhibitor)\n- Paper [94] PMID:34368657 — KEEP (ITK)\n- Paper [96] PMID:32049330 — KEEP (ITK)\n- Paper [98] PMID:21362141 — KEEP (Itk/NKT)\n- Paper [100] PMID:17652306 — KEEP (ITK/SLP-76)\n\n**Gene2pubmed additional papers:**\n- PMID:12477932 — EXCLUDE (cDNA resource, no mechanism)\n- PMID:28514442 — EXCLUDE (general interactome, no ITK-specific mechanism)\n- PMID:22939624 — KEEP (HSP90-client, ITK mentioned as client)\n- PMID:33961781 — EXCLUDE (general interactome)\n- PMID:21873635 — EXCLUDE (GO annotation)\n- PMID:16273093 — EXCLUDE (ErbB receptors)\n- PMID:15761153 — EXCLUDE (TGFβ pathway)\n- PMID:15489334 — EXCLUDE (MGC cDNA)\n- PMID:26344197 — EXCLUDE (metazoan complexes general)\n- PMID:8629002 — KEEP (BTK/SRC activation — BTK paper, but relevant to Tec family mechanism)\n- PMID:8630736 — KEEP (BTK autophosphorylation — relevant Tec family)\n- PMID:11830645 — KEEP (CypA regulation of Itk)\n- PMID:8985255 — KEEP (Itk intramolecular regulation)\n- PMID:19425169 — KEEP (ITK mutation/immunodeficiency)\n- PMID:10556826 — KEEP (Itk SH2 domain/SLP-76)\n- PMID:15144186 — EXCLUDE (phosphoproteomic methodology)\n- PMID:10022833 — EXCLUDE (Socs1/Kit, no ITK mechanism)\n- PMID:19240061 — EXCLUDE (GWAS coeliac disease)\n- PMID:8810341 — KEEP (Itk SH3 domain ligands)\n- PMID:9312162 — KEEP (Lck phosphorylates Itk)\n- PMID:24658140 — EXCLUDE (MaMTH method)\n- PMID:11598012 — EXCLUDE (PKCβ/BTK, not ITK specific)\n- PMID:7567982 — KEEP (Tsk/Itk activation by Gβγ)\n- PMID:20439541 — KEEP (ITK-SYK fusion kinase)\n- PMID:34857952 — EXCLUDE (DUSP4/6, no ITK)\n- PMID:25402006 — EXCLUDE (PPI prediction)\n- PMID:12190313 — EXCLUDE (CDK2 inhibitors)\n- PMID:30021884 — EXCLUDE (histone XL-MS)\n- PMID:22289921 — KEEP (ITK mutations/EBV-LPD)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"The kinase activity of Tsk/Itk is stimulated by G protein βγ subunits, demonstrated by co-transfection assays and in vitro reconstitution with purified bovine brain Gβγ subunits and immunoprecipitated Tsk, indicating Itk can act as an effector of heterotrimeric G proteins.\",\n      \"method\": \"Co-transfection assay and in vitro reconstitution with purified Gβγ subunits\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 (in vitro reconstitution) + Weak (single lab, single study)\",\n      \"pmids\": [\"7567982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The Itk SH3 domain binds specific proline-rich ligands including Sam68, Wiskott-Aldrich Syndrome protein (WASP), hnRNP-K, Grb-2, Cbl, and Fyn from TCR-stimulated Jurkat T cells, with the optimal SH3 binding motif defined by phage display library screening.\",\n      \"method\": \"Phage display library screening, SH3 domain pulldown from T cell lysates, deletion variant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal pulldowns with multiple binding partners, phage display motif mapping, replicated with multiple proteins\",\n      \"pmids\": [\"8810341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The Itk SH3 domain and proline-rich region interact intramolecularly, as determined by multidimensional NMR structure of an Itk fragment, representing the first example of intramolecular SH3-ligand interaction in a Tec family kinase. This interaction prevents the SH3 domain and proline-rich region from binding protein ligands (Sam68 and Grb-2), constituting an autoinhibitory mechanism.\",\n      \"method\": \"Multidimensional NMR structure determination, competitive binding assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with functional validation of autoinhibitory mechanism\",\n      \"pmids\": [\"8985255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Lck directly transphosphorylates Itk on Tyr511 within the activation loop of the kinase domain, leading to increased Itk kinase activity. This was demonstrated by co-expression of recombinant Itk and Lck in a baculovirus system, and mutation of Tyr511 to Phe abolished Itk kinase activity.\",\n      \"method\": \"Baculovirus co-expression of recombinant proteins, in vitro kinase assay, site-directed mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro phosphorylation with mutagenesis confirming the critical activation-loop tyrosine\",\n      \"pmids\": [\"9312162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Itk-deficient mice exhibit reduced primary cytotoxic T-lymphocyte (CTL) responses (by 2–6 fold) to LCMV, vaccinia virus, and VSV infection, while antiviral B cell antibody responses are unaffected. Exogenous IL-2 rescues in vitro CTL responses in Itk-deficient cells, indicating Itk is required for optimal T-cell but not B-cell antiviral immunity.\",\n      \"method\": \"Genetic knockout mouse model, ex vivo CTL assay, cytokine rescue experiment\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, cytokine rescue providing mechanistic insight\",\n      \"pmids\": [\"9311799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The SH2 domains of Btk and Itk selectively bind tyrosine-phosphorylated SLP-65 (in B cells) and SLP-76 (in T cells), respectively, in activated lymphocytes. This restricted SH2 binding specificity is required for phospholipase C-γ phosphorylation and Ca²⁺ mobilization downstream of antigen receptors.\",\n      \"method\": \"SH2 domain binding assays with T/B cell lysates, co-immunoprecipitation from activated lymphocytes\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding experiments in primary cells, linked to downstream PLCγ function\",\n      \"pmids\": [\"10556826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The Itk pleckstrin homology (PH) domain directs constitutive association with buoyant membrane rafts (primary sites of TCR activation) enriched in Lck and LAT. Deficiency of PTEN in Jurkat cells leads to elevated PI-3,4,5-P₃ at the plasma membrane, causing constitutive membrane localization of Itk and hyperresponsiveness to TCR stimulation. PTEN re-expression or PI3K inhibition redistributes Itk to the cytosol and normalizes signaling.\",\n      \"method\": \"Subcellular fractionation, Western blotting, PI3K inhibitor treatment, PTEN re-expression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with functional consequence, multiple orthogonal methods\",\n      \"pmids\": [\"10958690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Itk forms multivalent interactions with the TCR-proximal signaling complex: (1) its PH domain inositide-binding pocket recruits Itk to buoyant membrane rafts where Lck and LAT reside, enabling transphosphorylation; (2) the proline-rich region binds Grb2 and LAT; (3) SH3 and SH2 domains cooperatively interact with Syk-phosphorylated SLP-76. Kinase-inactive Itk antagonizes SLP-76-dependent NF-AT activation in a PH/proline-rich/SH2-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assays, dominant-negative Itk constructs, NF-AT reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, cooperative domain interactions mapped, functional readout with NF-AT reporter\",\n      \"pmids\": [\"10636929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The peptidyl-prolyl isomerase cyclophilin A (CypA) inhibits Itk catalytic activity through its isomerase activity. NMR structural studies combined with mutagenesis reveal a proline-dependent conformational switch within the Itk SH2 domain that regulates substrate recognition and mediates interactions with the CypA active site. CypA and Itk form a stable complex in Jurkat T cells that is disrupted by cyclosporin A treatment, and phosphorylation of Itk and PLCγ1 is increased following cyclosporin A treatment.\",\n      \"method\": \"NMR structural analysis, mutational analysis, co-immunoprecipitation from Jurkat T cells, cyclosporin A treatment, kinase activity assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with mutagenesis and cell-based validation, mechanistically connects CypA isomerase activity to Itk regulation\",\n      \"pmids\": [\"11830645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Two selective small-molecule inhibitors of Itk (BMS-488516 and BMS-509744) potently inhibit Itk kinase activity and block TCR-induced PLCγ1 tyrosine phosphorylation, calcium mobilization, IL-2 secretion, and T-cell proliferation in vitro in human and mouse cells. BMS-509744 significantly diminishes lung inflammation in a mouse model of ovalbumin-induced allergic asthma, validating Itk as a therapeutic target for Th2-mediated inflammatory diseases.\",\n      \"method\": \"In vitro kinase assay, calcium mobilization assay, cytokine ELISA, T-cell proliferation assay, murine ovalbumin asthma model\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective inhibitors with multiple in vitro and in vivo readouts, mechanistically links Itk to PLCγ1 signaling and Th2 inflammation\",\n      \"pmids\": [\"15323564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Itk has a kinase-independent scaffolding function in TCR-induced actin polarization: Itk is constitutively associated with the Vav guanine nucleotide exchange factor, and loss of Itk (by siRNA) reduces Vav recruitment to the antigen contact site and disrupts actin polarization. Both wild-type and kinase-inactive Itk rescue actin polarization defects, but Itk with mutations in the PH or SH2 domains cannot. Membrane-targeted Vav (Vav-CAAX) rescues the Itk siRNA phenotype.\",\n      \"method\": \"siRNA knockdown, re-expression of wild-type and mutant Itk, co-immunoprecipitation, actin polarization imaging, Vav-CAAX rescue\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including genetic rescue and domain mutants, defines scaffolding vs. kinase functions\",\n      \"pmids\": [\"15661896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SLP-76 not only recruits ITK but also directly maintains ITK kinase activity: the SLP-76/ITK complex interaction is required for both initiation and maintenance of ITK kinase activity, enabling ITK to phosphorylate PLCγ1. This places SLP-76 as more than a neutral adaptor — it actively sustains ITK catalytic function for downstream TCR-stimulated Ca²⁺ mobilization.\",\n      \"method\": \"Biochemical analysis of SLP-76/ITK complex, kinase activity assays\",\n      \"journal\": \"Science's STKE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review/synthesis with mechanistic model supported by cited biochemical data, single source\",\n      \"pmids\": [\"17652306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ITK is required for Th2 cytokine production (IL-4, IL-5, IL-13), actin reorganization, PLCγ activation, calcium mobilization, and NFAT transcription factor activation downstream of TCR, CD28, CD2, CXCR4, and FcεR signaling in T cells, NKT cells, and mast cells.\",\n      \"method\": \"Genetic Itk knockout studies, pharmacological inhibition studies reviewed\",\n      \"journal\": \"Current topics in medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesizes multiple KO and pharmacological studies; reviewed evidence, not primary data\",\n      \"pmids\": [\"19689375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In the absence of Itk (and Rlk), TCR signaling is impaired with defects in MAPK activation, Ca²⁺ mobilization, and actin polymerization. Itk and Rlk regulate the development of conventional vs. innate CD4⁺ and CD8⁺ T-cell lineages; Itk-deficient mice show altered NKT and γδ T-cell populations, indicating signaling strength via Itk determines conventional versus innate lymphocyte lineage commitment.\",\n      \"method\": \"Genetic knockout mouse models (Itk⁻/⁻, Rlk⁻/⁻Itk⁻/⁻), T-cell subset phenotyping\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO models with defined developmental phenotypes, replicated across studies\",\n      \"pmids\": [\"19290924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Homozygous missense mutation R335W in the SH2 domain of ITK causes fatal EBV-associated lymphoproliferative disease in two girls. The R335W mutation destabilizes the ITK SH2 domain (in silico modeling) and renders the protein nearly undetectable by Western blot when expressed in 293T cells, indicating protein instability. Patients show NKT cell absence and high eomesodermin in CD8⁺ cells, phenocopying murine Itk deficiency.\",\n      \"method\": \"SNP array linkage analysis, whole-exome sequencing, in silico protein modeling, Western blot of mutant ITK in 293T cells, flow cytometric immunophenotyping\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetics linked to protein instability with structural prediction and cell-based protein expression data; multiple orthogonal methods\",\n      \"pmids\": [\"19425169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ITK functions downstream of the TCR to regulate phospholipase C-gamma (PLCγ), with its kinase activity, domain interactions (PH, SH3, SH2, kinase domain), and substrate recognition mechanisms established. ITK controls development of conventional versus innate αβ and γδ T-cell subsets, and regulates effector T-cell differentiation and cytokine gene expression.\",\n      \"method\": \"Reviewed crystallographic structures, enzymatic studies, genetic models\",\n      \"journal\": \"Cold Spring Harbor perspectives in biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — synthesis of multiple structural and genetic studies across labs, highly cited review\",\n      \"pmids\": [\"20519342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The ITK-SYK fusion kinase (from chromosomal translocation t(5;9)(q33;q22) in peripheral T cell lymphoma) constitutively associates with lipid rafts in T cells and drives antigen-independent phosphorylation of TCR-proximal proteins, activating downstream pathways mimicking TCR ligation (CD69 upregulation, IL-2 production, thymocyte deletion, peripheral T-cell activation). Conditional expression of ITK-SYK in mice induces highly malignant peripheral T cell lymphomas with 100% penetrance.\",\n      \"method\": \"Conditional transgenic mouse model, biochemical fractionation (lipid rafts), phosphoprotein analysis, T-cell activation assays, in vivo lymphoma model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo methods, 100% penetrant mouse model establishes oncogenic mechanism\",\n      \"pmids\": [\"20439541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Itk is required for the development of invariant NKT αβ cells and a smaller population of NKT-like γδ T cells; Itk-regulated signaling pathways produce different developmental outcomes (conventional vs. innate lineage) in these cell subsets, suggesting the same Itk-regulated TCR signaling pathway is interpreted differently depending on cellular context.\",\n      \"method\": \"Itk genetic knockout mouse models, T-cell subset flow cytometric analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO model with defined phenotypic readout; mechanistic interpretation is inferential\",\n      \"pmids\": [\"21362141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss-of-function mutations in ITK distributed across the entire protein (missense R29H; nonsense/indel D500T,F501L,M503X) cause EBV-associated lymphoproliferative disorders. Wild-type ITK but not mutants rescues defective calcium flux in murine Itk⁻/⁻ T cells. The R29H mutation in the PH domain dramatically reduces binding to phosphatidylinositol monophosphates (PI(3)P, PI(4)P, PI(5)P) and higher-order PIP species. Mutations reduce ITK protein half-life by 25–69% compared to wild-type (t½ = 107 min).\",\n      \"method\": \"Calcium flux rescue assay in murine Itk⁻/⁻ T cells, pulse-chase protein stability assay, PH domain phosphoinositide binding assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical assays (Ca²⁺ rescue, PH binding, pulse-chase), maps mutations to PH-domain phosphoinositide binding function\",\n      \"pmids\": [\"22289921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD28-activated ITK specifically licenses autoreactive T cells to traffic from secondary lymphoid organs into target tissues to mount destructive autoimmune responses. Concurrent ablation of ITK in Ctla4⁻/⁻ mice blocks tissue infiltration by self-reactive T cells without preventing their activation or proliferation in lymphoid organs. ITK inhibitors phenocopy the null mutant and prevent pancreatic islet infiltration by diabetogenic T cells.\",\n      \"method\": \"Genetic double-knockout (Itk⁻/⁻;Ctla4⁻/⁻) mice, adoptive transfer, ITK inhibitor treatment, pancreatic islet histology\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (double KO) plus pharmacological validation in disease models, defines ITK role in T-cell trafficking vs. activation\",\n      \"pmids\": [\"24270545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ITK inhibitor PRN694 (selective covalent inhibitor of ITK and RLK) blocks Th1 and Th17 differentiation and cytokine production in vitro. In a T-cell adoptive transfer colitis model, in vivo PRN694 administration markedly reduces disease progression, T-cell infiltration into the intestinal lamina propria, IFN-γ production, and P-selectin binding and CXCL11/CCL20-directed migration of Th1/Th17 cells.\",\n      \"method\": \"In vitro Th polarization assay, adoptive transfer colitis model, flow cytometry, cytokine ELISA, migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective covalent inhibitor with multiple in vitro and in vivo readouts linking ITK+RLK activity to Th1/Th17 differentiation and migration\",\n      \"pmids\": [\"26466958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Itk signaling promotes experimental autoimmune encephalomyelitis (EAE): Itk⁻/⁻ mice show reduced disease severity, and adoptive transfer of Itk⁻/⁻ CD4⁺ T cells produces lower disease severity in T cell-deficient recipients. Itk⁻/⁻ CD4⁺ T cells show defective response to myelin antigen, displacement of filamentous actin from the CD4 co-receptor, impaired transmigration across brain endothelial barriers, and reduced Th1/Th17 cytokine production with skewed Teff/Treg ratios.\",\n      \"method\": \"KO mouse model, adoptive transfer, EAE induction, in vitro transendothelial migration assay, actin imaging, cytokine measurement\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO plus adoptive transfer (epistasis), mechanistically links Itk to actin dynamics, CNS transmigration, and cytokine production\",\n      \"pmids\": [\"25568116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ITK kinase activity is required for TCR-induced development of Type 1 regulatory T (Tr1) cells in various organs and mucosal tissues during parasitic and viral infections. Downstream of ITK, Ras activity is responsible for Tr1 cell induction: constitutively active HRas rescues IRF4 expression and Tr1 cell differentiation in Itk⁻/⁻ cells. The transcription factor IRF4 mediates ITK's effect on Tr1 cell differentiation, as IRF4 overexpression restores Tr1 development and suppressive function of Itk-deficient cells.\",\n      \"method\": \"Itk⁻/⁻ mouse model, constitutively active HRas rescue, IRF4 overexpression rescue, in vivo infection models, flow cytometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (KO + constitutively active Ras rescue + IRF4 rescue), multiple in vivo contexts\",\n      \"pmids\": [\"28635957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Both genetic loss-of-function (novel ITK mutation) and chemical inhibition of ITK (ibrutinib) result in reduced Th17 generation and IL-17A/IL-22/GM-CSF production in humans, with reciprocally increased IFN-γ (Th1) production. ITK deficiency in a human patient also reduces peripheral ILC2 and ILC3 populations. IBrutinib blocks Th17 generation and augments FoxP3 expression at low doses in Treg cultures.\",\n      \"method\": \"Whole exome sequencing, flow cytometry, cytokine measurement, ibrutinib pharmacological inhibition of ex vivo human T cells\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetic loss-of-function corroborated by pharmacological inhibition with orthogonal readouts in human cells\",\n      \"pmids\": [\"31025232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ITK signals downstream of TCR differentially control effector T-cell differentiation: the Ras/MAPK pathway downstream of ITK controls TH17, Foxp3⁺ Treg, and Tr1 cell fate decisions, supporting a model in which ITK signaling strength controls a T-cell effector differentiation decision point.\",\n      \"method\": \"Genetic KO studies, constitutively active Ras rescue, IRF4 expression analysis (reviewed mechanistic findings)\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesizes multiple primary experimental findings; review article, not primary data\",\n      \"pmids\": [\"32049330\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ITK (IL-2-inducible T-cell kinase), a Tec-family non-receptor tyrosine kinase predominantly expressed in T cells, is activated downstream of TCR stimulation via Lck-mediated transphosphorylation of its activation-loop Tyr511, with membrane recruitment driven by PI3K-generated phosphoinositides binding its PH domain; once activated and assembled into a multivalent complex with SLP-76, LAT, and Grb2 through cooperative SH3/SH2/PH domain interactions, ITK phosphorylates PLCγ1 to drive Ca²⁺ mobilization and NFAT activation, while also performing kinase-independent scaffolding of Vav to regulate actin polarization; ITK activity is negatively regulated by an intramolecular SH3–proline-rich region interaction and by cyclophilin A-mediated prolyl isomerization of the SH2 domain, and is essential for Th2/Th17 cytokine production, conventional vs. innate T-cell lineage commitment, Tr1 cell development (via Ras/IRF4), and autoreactive T-cell trafficking to target tissues, with loss-of-function mutations causing fatal EBV-associated lymphoproliferation in humans.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ITK is a Tec family non-receptor tyrosine kinase that functions as the predominant TCR-proximal kinase coupling antigen receptor engagement to PLCγ1 activation, calcium mobilization, NFAT signaling, and cytokine production in T cells [PMID:15323564, PMID:20519342]. ITK is recruited to lipid raft–associated LAT signaling complexes via its PH domain, where it is transphosphorylated and activated by SLP-76, which binds cooperatively through ITK's SH3 and SH2 domains to stimulate kinase activity toward PLCγ1 [PMID:10636929, PMID:17652306]; independently of its kinase activity, ITK scaffolds Vav to the immune synapse, enabling TCR-driven actin polarization required for T cell migration and effector function [PMID:15661896]. ITK-mediated TCR signal strength governs the balance between conventional and innate T cell lineage commitment, tunes Th1/Th2/Th17/Treg differentiation via the Ras–IRF4 axis, licenses autoreactive T cell trafficking into peripheral tissues, and is required for optimal antiviral CTL responses [PMID:19290924, PMID:28635957, PMID:24270545, PMID:9311799]. Loss-of-function mutations in human ITK cause combined immunodeficiency with impaired T cell proliferation, increased apoptosis, skewed cytokine production, and reduced innate lymphoid cell populations [PMID:31025232].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that ITK is functionally required in vivo for antiviral immunity: Itk-knockout mice showed reduced CTL responses and delayed viral clearance, demonstrating a non-redundant role in adaptive T cell immunity.\",\n      \"evidence\": \"Itk-/- mice challenged with LCMV, vaccinia, and VSV; ex vivo CTL killing assays and viral clearance kinetics\",\n      \"pmids\": [\"9311799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism downstream of ITK in CTL effector function undefined\", \"Relative contribution of ITK versus RLK not dissected\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defining the molecular architecture of ITK activation: the PH domain targets ITK to lipid raft–resident LAT/Lck complexes for transphosphorylation, while the SH3 and SH2 domains cooperatively bind SLP-76, linking ITK to the TCR signalosome and NFAT activation.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro binding assays, lipid raft fractionation, dominant-negative overexpression with NF-AT reporter\",\n      \"pmids\": [\"10636929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SLP-76 directly stimulates ITK catalytic activity or merely recruits it was unresolved\", \"Structural basis for cooperative SH3-SH2 engagement not determined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Pharmacological validation that ITK kinase activity is required for PLCγ1 phosphorylation, calcium flux, IL-2 secretion, and T cell proliferation, confirming the catalytic function as the critical link between TCR engagement and downstream effector signaling.\",\n      \"evidence\": \"Selective ITK inhibitors (BMS-488516, BMS-509744) tested in kinase assays, PLCγ1 phosphorylation, calcium flux, IL-2 ELISA, proliferation assays, and murine asthma model\",\n      \"pmids\": [\"15323564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Off-target effects on other Tec kinases not fully excluded\", \"Whether inhibitor-resistant phenotypes exist in vivo not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealing a kinase-independent scaffolding function: ITK constitutively associates with Vav and positions it at the immune synapse for TCR-driven actin polarization, a function rescued by kinase-dead ITK but not by PH or SH2 mutants.\",\n      \"evidence\": \"siRNA knockdown and rescue with WT, kinase-dead, and domain-mutant ITK; Co-IP of ITK-Vav; confocal imaging; Vav-CAAX rescue\",\n      \"pmids\": [\"15661896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the scaffolding function extends beyond Vav to other actin regulators unknown\", \"Structural basis of constitutive ITK-Vav interaction not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Establishing SLP-76 as a direct allosteric activator of ITK: SLP-76 not only recruits but stimulates and sustains ITK kinase activity toward PLCγ1, resolving the adaptor-versus-activator question.\",\n      \"evidence\": \"Biochemical kinase activity assays measuring ITK activation in presence/absence of SLP-76\",\n      \"pmids\": [\"17652306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Detailed kinetic parameters and structural basis of allosteric activation not provided in this source\", \"Whether other adaptors similarly regulate ITK catalysis untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"ITK-controlled TCR signal strength determines the developmental decision between conventional and innate T cell lineages: Itk/Rlk-deficient mice shift from conventional to innate-like CD4+ and CD8+ T cells, NKT cells, and γδ T cells.\",\n      \"evidence\": \"Itk-/- and Itk-/-Rlk-/- mice; flow cytometric analysis of thymic and peripheral T cell subsets; signaling assays\",\n      \"pmids\": [\"19290924\", \"21362141\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise TCR signal threshold distinguishing conventional from innate fate not quantified\", \"Cell-intrinsic versus microenvironmental contributions not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"ITK licenses autoreactive T cell trafficking into peripheral tissues without controlling their activation or proliferation in lymphoid organs, revealing a tissue-entry checkpoint controlled by ITK signaling.\",\n      \"evidence\": \"Itk-/-;Ctla4-/- double knockout mice, adoptive transfer, T cell trafficking assays, pharmacological ITK inhibition, diabetogenic T cell islet infiltration model\",\n      \"pmids\": [\"24270545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular intermediates between ITK and the tissue-homing machinery not identified\", \"Whether this mechanism operates identically in human autoimmune disease unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ITK signaling controls CD4+ T cell pathogenicity in autoimmune neuroinflammation by maintaining actin association with CD4 coreceptor, enabling transendothelial migration and Th1/Th17 cytokine production; pharmacological ITK/RLK inhibition suppresses Th1/Th17 differentiation and disease in colitis models.\",\n      \"evidence\": \"Itk-/- mice in EAE model, adoptive transfer, actin imaging, transendothelial migration assay; covalent ITK/RLK inhibitor PRN694 in Th polarization assays and adoptive transfer colitis\",\n      \"pmids\": [\"25568116\", \"26466958\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ITK inhibition affects already-differentiated effector T cells or only during priming unclear\", \"Therapeutic window and safety profile of ITK inhibition in chronic disease models not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of the Ras–IRF4 axis as the critical ITK-dependent signaling pathway for Tr1 cell differentiation: constitutively active Ras rescues IRF4 expression and Tr1 function in Itk-/- cells, placing ITK upstream of a defined transcriptional program.\",\n      \"evidence\": \"Itk-/- mice, retroviral rescue with HRas(V12) and IRF4, Tr1 differentiation assays, IL-10 production, parasitic/viral infection models\",\n      \"pmids\": [\"28635957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ITK activates Ras (direct phosphorylation versus adaptor-mediated) not mechanistically resolved\", \"Whether the same pathway operates in human Tr1 cells not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Human ITK loss-of-function mutation causes combined immunodeficiency with impaired T cell proliferation, increased apoptosis, skewed Th17/IFN-γ balance, and reduced ILC2/ILC3, validating murine findings in human immunology.\",\n      \"evidence\": \"Patient whole exome sequencing, flow cytometry, proliferation/apoptosis assays, cytokine profiling, ibrutinib pharmacological inhibition\",\n      \"pmids\": [\"31025232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Number of patients studied is limited; genotype-phenotype correlation across diverse mutations not established\", \"Effect of ITK deficiency on human innate-like T cell development not fully characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for SLP-76-mediated allosteric activation of ITK, the molecular mechanism by which ITK controls tissue-homing receptor expression, and whether kinase-dependent and scaffolding functions can be therapeutically uncoupled remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of an ITK–SLP-76 activation complex\", \"Molecular targets linking ITK to integrin/selectin-dependent tissue trafficking not identified\", \"Whether kinase-independent scaffolding and kinase-dependent catalytic functions can be selectively targeted therapeutically is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 3, 6, 12]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 2, 3, 5, 6, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 5, 7, 9, 10, 11, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SLP-76\", \"PLCγ1\", \"Vav\", \"LAT\", \"Lck\", \"Grb2\", \"RLK\", \"IRF4\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ITK is a Tec-family non-receptor tyrosine kinase that serves as a central integrator of T-cell receptor (TCR) signaling, coupling antigen recognition to downstream effector programs including calcium mobilization, cytokine production, actin polarization, and T-cell differentiation. Activated by Lck-mediated transphosphorylation of Tyr511 upon PI3K-dependent PH-domain-mediated membrane recruitment, ITK assembles into a multivalent signaling complex with SLP-76, LAT, and Grb2 through cooperative SH3/SH2/PH domain interactions and phosphorylates PLCγ1 to drive Ca²⁺ flux and NFAT activation; its catalytic activity is negatively regulated by intramolecular SH3–proline-rich autoinhibition and cyclophilin A-mediated prolyl isomerization of the SH2 domain [PMID:9312162, PMID:10636929, PMID:8985255, PMID:11830645]. ITK also performs a kinase-independent scaffolding function by constitutively associating with Vav to direct actin polarization at the immunological synapse, and controls conventional versus innate T-cell lineage commitment, Th2/Th17 cytokine production, Tr1 cell development via the Ras/IRF4 axis, and autoreactive T-cell trafficking to target tissues [PMID:15661896, PMID:19290924, PMID:28635957, PMID:24270545]. Loss-of-function mutations in ITK cause fatal EBV-associated lymphoproliferative disease in humans, with absent NKT cells phenocopying the murine knockout [PMID:19425169, PMID:22289921].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"The identification that Gβγ subunits stimulate ITK kinase activity raised the possibility that ITK integrates signals from heterotrimeric G proteins in addition to receptor tyrosine kinases.\",\n      \"evidence\": \"Co-transfection and in vitro reconstitution with purified bovine brain Gβγ subunits and immunoprecipitated ITK\",\n      \"pmids\": [\"7567982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding not independently replicated\", \"Physiological relevance of Gβγ–ITK coupling in primary T cells not established\", \"No identification of upstream GPCR\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapping the SH3 domain interactome (Sam68, WASP, Grb2, Cbl, Fyn) established ITK as a multi-partner signaling hub whose SH3 domain engages distinct proline-rich effectors upon TCR stimulation.\",\n      \"evidence\": \"Phage display motif definition and SH3 pulldown from TCR-stimulated Jurkat lysates\",\n      \"pmids\": [\"8810341\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of each individual SH3 interaction not dissected\", \"Relative affinities and competitive binding in vivo unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Three foundational discoveries resolved ITK activation and autoinhibition: NMR revealed the first intramolecular SH3–proline-rich autoinhibitory interaction in a Tec kinase; reconstitution showed Lck transphosphorylates Tyr511 to activate ITK; and Itk-knockout mice demonstrated a non-redundant requirement for optimal antiviral CTL responses.\",\n      \"evidence\": \"Multidimensional NMR structure with competitive binding assays; baculovirus co-expression with Y511F mutagenesis and in vitro kinase assay; Itk⁻/⁻ mice with LCMV/vaccinia/VSV infection and IL-2 rescue\",\n      \"pmids\": [\"8985255\", \"9312162\", \"9311799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length structural model of autoinhibited ITK not available\", \"Whether Lck is the sole activating kinase in vivo undetermined\", \"Mechanism by which ITK loss reduces CTL responses beyond IL-2 signaling not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The demonstration that ITK's SH2 domain selectively binds phospho-SLP-76 linked ITK recruitment to the adaptor scaffold required for PLCγ phosphorylation and Ca²⁺ mobilization.\",\n      \"evidence\": \"SH2 domain binding assays and co-immunoprecipitation from activated T-cell lysates\",\n      \"pmids\": [\"10556826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of the ITK–SLP-76 complex in living cells not measured\", \"Contribution of other SLP-76-binding kinases not delineated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Membrane recruitment was mechanistically resolved: the PH domain targets ITK to PIP₃-enriched lipid rafts containing Lck and LAT, and PTEN opposes this localization—establishing PI3K/PTEN as upstream regulators of ITK spatial activation. Concurrently, cooperative multivalent interactions (PH–PIP₃, proline-rich–Grb2/LAT, SH3/SH2–SLP-76) were shown to assemble ITK into the TCR signalosome, with kinase-dead ITK acting as a dominant negative for NFAT activation.\",\n      \"evidence\": \"Subcellular fractionation with PTEN re-expression and PI3K inhibition; co-IP and in vitro binding with domain mutants and NFAT reporter assay\",\n      \"pmids\": [\"10958690\", \"10636929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each multivalent interaction to complex stability unmeasured\", \"Real-time imaging of ITK membrane dynamics not performed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The discovery that cyclophilin A inhibits ITK through prolyl isomerization of the SH2 domain introduced a novel post-translational regulatory mechanism and provided an unexpected link between ITK regulation and cyclosporin A pharmacology.\",\n      \"evidence\": \"NMR structural analysis of the SH2 proline switch, co-IP from Jurkat cells, cyclosporin A disruption of CypA–ITK complex with increased PLCγ1 phosphorylation\",\n      \"pmids\": [\"11830645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of CypA to ITK regulation versus calcineurin inhibition by cyclosporin A not separated\", \"Whether other peptidyl-prolyl isomerases regulate ITK is unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Separation of kinase-dependent and kinase-independent functions was achieved: ITK scaffolds Vav recruitment to the immunological synapse via PH and SH2 domains to direct actin polarization independently of its catalytic activity.\",\n      \"evidence\": \"siRNA knockdown with rescue by wild-type versus kinase-dead and domain-mutant ITK constructs; Vav-CAAX rescue of actin polarization\",\n      \"pmids\": [\"15661896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ITK's scaffolding and kinase functions are temporally coordinated is unresolved\", \"Structural basis of the constitutive ITK–Vav interaction undefined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"ITK was established as a master regulator of T-cell lineage fate: Itk⁻/⁻ mice show expansion of innate-like T cells (NKT, γδ) at the expense of conventional αβ T cells, indicating that ITK-dependent TCR signal strength determines the conventional versus innate lineage decision. Simultaneously, human genetics proved ITK essential for EBV control, as homozygous R335W (SH2 domain) caused fatal lymphoproliferative disease with absent NKT cells.\",\n      \"evidence\": \"Itk⁻/⁻ and Rlk⁻/⁻Itk⁻/⁻ KO mouse models with flow cytometric T-cell subset analysis; human exome sequencing, in silico modeling, Western blot of mutant protein in 293T cells, immunophenotyping\",\n      \"pmids\": [\"19290924\", \"19425169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular threshold of TCR signal strength that toggles lineage fate not quantified\", \"Whether ITK deficiency-related lymphoproliferation reflects solely NKT cell absence or additional immune defects is unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Additional human loss-of-function mutations mapped across ITK (PH domain R29H; kinase domain truncations) confirmed genotype–phenotype correlations: the R29H mutation specifically ablates PH domain phosphoinositide binding and all mutations reduce protein half-life, directly connecting lipid-binding-driven membrane recruitment and protein stability to human disease.\",\n      \"evidence\": \"Calcium flux rescue in murine Itk⁻/⁻ T cells, pulse-chase protein stability assay, PH domain–phosphoinositide binding assay\",\n      \"pmids\": [\"22289921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of R29H PH domain not determined\", \"Whether reduced half-life is due to misfolding or active degradation pathway not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A non-redundant role for ITK in licensing autoreactive T-cell tissue infiltration (distinct from activation/proliferation) was demonstrated: ITK ablation in Ctla4⁻/⁻ mice blocks self-reactive T-cell egress from lymphoid organs without suppressing their activation, positioning ITK as a specific target for autoimmune tissue destruction.\",\n      \"evidence\": \"Itk⁻/⁻;Ctla4⁻/⁻ double-KO mice, adoptive transfer, ITK inhibitor treatment, pancreatic islet histology\",\n      \"pmids\": [\"24270545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which ITK controls tissue-homing molecule expression not fully defined\", \"Whether this trafficking role is kinase-dependent or scaffolding-dependent is unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Pharmacological and genetic studies converged to show ITK controls Th17 differentiation and T-cell transendothelial migration: selective covalent ITK/RLK inhibitor PRN694 blocked Th1/Th17 cytokines and reduced colitis severity, while Itk⁻/⁻ CD4⁺ T cells showed impaired transmigration across brain endothelial barriers and reduced EAE severity with altered Teff/Treg ratios.\",\n      \"evidence\": \"In vitro Th polarization, adoptive transfer colitis model, PRN694 treatment; Itk⁻/⁻ EAE model with in vitro transendothelial migration assay and actin imaging\",\n      \"pmids\": [\"26466958\", \"25568116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of ITK versus RLK to PRN694 efficacy not separated\", \"Actin–CD4 coreceptor displacement mechanism not molecularly defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The downstream signaling axis was extended: ITK kinase activity drives Tr1 cell development through Ras-dependent IRF4 expression, as constitutively active HRas and IRF4 overexpression each rescue Tr1 differentiation in Itk⁻/⁻ cells across parasitic and viral infection models.\",\n      \"evidence\": \"Itk⁻/⁻ mice with constitutively active HRas or IRF4 rescue, in vivo infection models, flow cytometry\",\n      \"pmids\": [\"28635957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link between ITK kinase activity and Ras activation not established\", \"Whether ITK–Ras–IRF4 axis operates in human Tr1 cells not confirmed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Human validation confirmed ITK's role in Th17 biology: a novel ITK loss-of-function patient and ibrutinib treatment both reduced Th17 generation and IL-17A/IL-22/GM-CSF production while increasing IFN-γ, and reduced ILC2/ILC3 populations, extending ITK function beyond adaptive T cells to innate lymphoid cells.\",\n      \"evidence\": \"Human exome sequencing, ex vivo ibrutinib treatment of human T cells, flow cytometry, cytokine measurement\",\n      \"pmids\": [\"31025232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ibrutinib also inhibits BTK; ITK-selective effects in human cells require confirmation with cleaner tools\", \"Whether ILC2/ILC3 reduction is cell-intrinsic or secondary to T-cell dysfunction unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length structure of autoinhibited ITK, the molecular mechanism by which ITK controls tissue-homing programs independently of proliferative signals, the direct biochemical connection between ITK and Ras activation, and whether kinase-dependent versus scaffolding functions can be pharmacologically separated for therapeutic benefit.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length autoinhibited structure resolved\", \"Kinase-dependent vs. scaffolding functions not pharmacologically separable yet\", \"ITK–Ras link lacks direct biochemical reconstitution\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 9, 15]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [10, 7]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 7, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 9, 12, 13, 14, 19, 20, 22, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 7, 8, 9, 15]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [13, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 16, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"LCK\",\n      \"SLP76\",\n      \"PLCG1\",\n      \"VAV1\",\n      \"GRB2\",\n      \"PPIA\",\n      \"LAT\",\n      \"WASP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}